Ignacio F Mata

List of Publications by Year
in descending order

90	7,386	94433 37	56724 83
papers	citations	h-index	g-index

95	95	95	9610
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	RIC3 variants are not associated with Parkinson's disease in large European, Latin American, or East Asian cohorts. Neurobiology of Aging, 2022, 109, 264-268.	3.1	0
2	Looking back the importance of genetics in a patient with Parkinson disease and deep brain stimulation. Parkinsonism and Related Disorders, 2022, , .	2.2	0
3	A Review on Response to Device-Aided Therapies Used in Monogenic Parkinsonism and GBA Variants Carriers: A Need for Guidelines and Comparative Studies. Journal of Parkinson's Disease, 2022, 12, 1703-1725.	2.8	4
4	Polygenic risk prediction and SNCA haplotype analysis in a Latino Parkinson's disease cohort. Parkinsonism and Related Disorders, 2022, 102, 7-15.	2.2	2
5	Cognition as a mediator for gait and balance impairments in GBA-related Parkinsonâ€™s disease. Npj Parkinson's Disease, 2022, 8, .	5.3	1
6	When does postural instability appear in monogenic parkinsonisms? An individual-patient meta-analysis. Journal of Neurology, 2021, 268, 3203-3211.	3.6	16
7	Genomeâ€Wide Analysis of Copy Number Variation in Latin American Parkinson's Disease Patients. Movement Disorders, 2021, 36, 434-441.	3.9	12
8	Dementia in Latin America: Paving the way toward a regional action plan. Alzheimer's and Dementia, 2021, 17, 295-313.	0.8	68
9	ATP1A3-Related Disorders: An Ever-Expanding Clinical Spectrum. Frontiers in Neurology, 2021, 12, 637890.	2.4	28
10	Characterizing the Genetic Architecture of Parkinson's Disease in Latinos. Annals of Neurology, 2021, 90, 353-365.	5.3	48
11	Should we start integrating genetic data in decision-making on device-aided therapies in Parkinson disease? A point of view. Parkinsonism and Related Disorders, 2021, 88, 51-57.	2.2	14
12	Genetics of Parkinsonâ€™s disease in Brazil: a systematic review of monogenic forms. Arquivos De Neuro-Psiquiatria, 2021, 79, 612-623.	0.8	3
13	Editorial: Genotype-Phenotype Correlation in Parkinsonian Conditions. Frontiers in Neurology, 2021, 12, 743953.	2.4	0
14	Clinical and Genetic Analysis of Costa Rican Patients With Parkinson's Disease. Frontiers in Neurology, 2021, 12, 656342.	2.4	4
15	Tracing the Distribution of European Lactase Persistence Genotypes Along the Americas. Frontiers in Genetics, 2021, 12, 671079.	2.3	3
16	Genetic parkinsonisms and cancer: a systematic review and meta-analysis. Reviews in the Neurosciences, 2021, 32, 159-167.	2.9	8
17	Navigating the open sea of commercial genetic testing in Parkinsonâ€™s Disease. Parkinsonism and Related Disorders, 2021, 92, 105-106.	2.2	1
18	Novel compound heterozygous FBXO7 mutations in a family with early onset Parkinson's disease. Parkinsonism and Related Disorders, 2020, 80, 142-147.	2.2	8

#	Article	IF	Citations
19	Sensorimotor Inhibition and Mobility in Genetic Subgroups of Parkinson's Disease. Frontiers in Neurology, 2020, 11, 893.	2.4	3
20	Multivariate prediction of dementia in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2020, 6, 20.	5.3	25
21	Diagnostic prediction model for levodopa-induced dyskinesia in Parkinsonâ€™s disease. Arquivos De Neuro-Psiquiatria, 2020, 78, 206-216.	0.8	10
22	Driving genotype treatment options down the right path(way). Movement Disorders, 2019, 34, 1811-1813.	3.9	1
23	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology, 2019, 92, 329-337.	1.1	194
24	Genetics of cognitive trajectory in Brazilians: 15 years of follow-up from the BambuÃ-Epigen Cohort Study of Aging. Scientific Reports, 2019, 9, 18085.	3.3	6
25	The distribution and risk effect of GBA variants in a large cohort of PD patients from Colombia and Peru. Parkinsonism and Related Disorders, 2019, 63, 204-208.	2.2	31
26	Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease. Parkinsonism and Related Disorders, 2018, 50, 29-36.	2.2	94
27	Association of a neuronal nitric oxide synthase gene polymorphism with levodopa-induced dyskinesia in Parkinson's disease. Nitric Oxide - Biology and Chemistry, 2018, 74, 86-90.	2.7	8
28	Age- and disease-dependent increase of the mitophagy marker phospho-ubiquitin in normal aging and Lewy body disease. Autophagy, 2018, 14, 1404-1418.	9.1	87
29	Intrafamilial variable phenotype including corticobasal syndrome in a family with p.P301L mutation in the MAPT gene: first report in South America. Neurobiology of Aging, 2017, 53, 195.e11-195.e17.	3.1	9
30	Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease. Neurobiology of Aging, 2017, 56, 211.e1-211.e7.	3.1	37
31	LARGEâ€PD: Examining the genetics of Parkinson's disease in Latin America. Movement Disorders, 2017, 32, 1330-1331.	3.9	34
32	Variable frequency of LRRK2 variants in the Latin American research consortium on the genetics of Parkinsonâ€™s disease (LARGE-PD), a case of ancestry. Npj Parkinson's Disease, 2017, 3, 19.	5.3	28
33	Some aspects of the validity of the Montreal Cognitive Assessment (MoCA)for evaluating cognitive impairment in Brazilian patients with Parkinson's disease. Dementia E Neuropsychologia, 2016, 10, 333-338.	0.8	18
34	Association ofGBAMutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. JAMA Neurology, 2016, 73, 1217.	9.0	185
35	The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, 171, 925-930.	1.7	17
36	GBA Variants are associated with a distinct pattern of cognitive deficits in <scp>P</scp>arkinson's disease. Movement Disorders, 2016, 31, 95-102.	3.9	158

#	Article	IF	Citations
37	Precision Medicine. American Journal of Pathology, 2016, 186, 500-506.	3.8	49
38	The RAB39B p.G192R mutation causes X-linked dominant Parkinsonâ€™s disease. Molecular Neurodegeneration, 2015, 10, 50.	10.8	91
39	Screening of cognitive impairment in patients with Parkinson's disease: diagnostic validity of the Brazilian versions of the Montreal Cognitive Assessment and the Addenbrooke's Cognitive Examination-Revised. Arquivos De Neuro-Psiquiatria, 2015, 73, 929-933.	0.8	25
40	Cognitive profile of LRRK2â€related Parkinson's disease. Movement Disorders, 2015, 30, 728-733.	3.9	64
41	A Peruvian family with a novel PARK2 mutation: Clinical andÂpathological characteristics. Parkinsonism and Related Disorders, 2015, 21, 444-448.	2.2	20
42	The screening of the 3â€²UTR sequence of LRRK2 identified an association between the rs66737902 polymorphism and Parkinsonâ€™s disease. Journal of Human Genetics, 2014, 59, 346-348.	2.3	14
43	APOE,MAPT, andSNCAGenes and Cognitive Performance in Parkinson Disease. JAMA Neurology, 2014, 71, 1405.	9.0	172
44	Evaluation of mild cognitive impairment subtypes in Parkinson's disease. Movement Disorders, 2014, 29, 756-764.	3.9	53
45	Alpha-synuclein transcript isoforms in three different brain regions from Parkinson's disease and healthy subjects in relation to the SNCA rs356165/rs11931074 polymorphisms. Neuroscience Letters, 2014, 562, 45-49.	2.1	30
46	Association mapping of the PARK10 region for Parkinson's disease susceptibility genes. Parkinsonism and Related Disorders, 2014, 20, 93-98.	2.2	16
47	Clinical and molecular studies reveal a PSEN1 mutation (L153V) in a Peruvian family with early-onset Alzheimer's disease. Neuroscience Letters, 2014, 563, 140-143.	2.1	7
48	Mosaicism of alpha-synuclein gene rearrangements: Report of two unrelated cases of early-onset parkinsonism. Parkinsonism and Related Disorders, 2014, 20, 558-561.	2.2	14
49	Identification of a Japanese family with LRRK2 p.R1441G-related Parkinson's disease. Neurobiology of Aging, 2014, 35, 2656.e17-2656.e23.	3.1	24
50	Mutational Screening of PARKIN Identified a 3â€² UTR Variant (rs62637702) Associated with Parkinsonâ€™s Disease. Journal of Molecular Neuroscience, 2013, 50, 264-269.	2.3	11
51	C9orf72 Hexanucleotide Repeat Expansion and Guam Amyotrophic Lateral Sclerosisâ€“Parkinsonism-Dementia Complex. JAMA Neurology, 2013, 70, 742.	9.0	22
52	Risk prediction for complex diseases: application to Parkinson disease. Genetics in Medicine, 2013, 15, 361-367.	2.4	14
53	APOE Ïµ4 Increases Risk for Dementia in Pure Synucleinopathies. JAMA Neurology, 2013, 70, 223.	9.0	302
54	Altered splicing of ATP6AP2 causes X-linked parkinsonism with spasticity (XPDS). Human Molecular Genetics, 2013, 22, 3259-3268.	2.9	113

#	Article	IF	Citations
55	Novel <scp>Lrrk2</scp>â€p.<scp>S1761R</scp> mutation is not a common cause of Parkinson's disease in Spain. Movement Disorders, 2013, 28, 248-248.	3.9	1
56	Common variation in the LRRK2 gene is a risk factor for Parkinson's disease. Movement Disorders, 2012, 27, 1823-1826.	3.9	14
57	GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology, 2012, 79, 1944-1950.	1.1	138
58	A Search for SNCA 3â€² UTR Variants Identified SNP rs356165 as a Determinant of Disease Risk and Onset Age in Parkinsonâ€™s Disease. Journal of Molecular Neuroscience, 2012, 47, 425-430.	2.3	49
59	The UCHL1 S18Y polymorphism and Parkinsonâ€™s disease in a Japanese population. Parkinsonism and Related Disorders, 2011, 17, 473-475.	2.2	5
60	Lrrk2 p.Q1111H substitution and Parkinsonâ€™s disease in Latin America. Parkinsonism and Related Disorders, 2011, 17, 629-631.	2.2	15
61	Replication of MAPT and SNCA, but not PARK16â€18, as susceptibility genes for Parkinson's disease. Movement Disorders, 2011, 26, 819-823.	3.9	64
62	The Genetics of Parkinson Disease. Journal of Geriatric Psychiatry and Neurology, 2010, 23, 228-242.	2.3	259
63	SNCA Variant Associated With Parkinson Disease and Plasma Î±-Synuclein Level. Archives of Neurology, 2010, 67, 1350-6.	4.5	157
64	Genotypeâ€“phenotype correlates in Taiwanese patients with earlyâ€onset recessive parkinsonism. Movement Disorders, 2009, 24, 104-108.	3.9	24
65	LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease. Movement Disorders, 2009, 24, 1034-1041.	3.9	60
66	GCH1 in earlyâ€onset Parkinson's disease. Movement Disorders, 2009, 24, 2070-2075.	3.9	17
67	Lrrk2 R1441G-related Parkinsonâ€™s disease: evidence of a common founding event in the seventh century in Northern Spain. Neurogenetics, 2009, 10, 347-353.	1.4	41
68	Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease. New England Journal of Medicine, 2009, 361, 1651-1661.	27.0	1,747
69	LRRK2 mutations in patients with Parkinson's disease from Peru and Uruguay. Parkinsonism and Related Disorders, 2009, 15, 370-373.	2.2	45
70	Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Annals of Neurology, 2008, 64, 88-92.	5.3	207
71	Glucocerebrosidase Gene Mutations. Archives of Neurology, 2008, 65, 379-82.	4.5	188
72	Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain. Parkinsonism and Related Disorders, 2007, 13, 509-515.	2.2	48

#	Article	IF	Citations
73	Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease. Movement Disorders, 2007, 22, 389-392.	3.9	8
74	Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions. Acta Neuropathologica, 2007, 113, 601-606.	7.7	55
75	LRRK2: a common pathway for parkinsonism, pathogenesis and prevention?. Trends in Molecular Medicine, 2006, 12, 76-82.	6.7	86
76	Digenic parkinsonism: Investigation of the synergistic effects of PRKN and LRRK2. Neuroscience Letters, 2006, 410, 80-84.	2.1	52
77	Genetics of restless legs syndrome. Parkinsonism and Related Disorders, 2006, 12, 1-7.	2.2	14
78	LRRK2 in Parkinson's disease: protein domains and functional insights. Trends in Neurosciences, 2006, 29, 286-293.	8.6	439
79	LRRK2 mutations are a common cause of Parkinson's disease in Spain. European Journal of Neurology, 2006, 13, 391-394.	3.3	60
80	Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics, 2005, 6, 171-177.	1.4	237
81	LRRK2 mutations in Parkinson disease. Neurology, 2005, 65, 738-740.	1.1	134
82	LRRK2 mutations and Parkinsonism. Lancet, The, 2005, 365, 1229-1230.	13.7	33
83	Identification of a Novel LRRK2 Mutation Linked to Autosomal Dominant Parkinsonism: Evidence of a Common Founder across European Populations. American Journal of Human Genetics, 2005, 76, 672-680.	6.2	524
84	Homozygous partial genomic triplication of the parkin gene in early-onset parkinsonism. Neuroscience Letters, 2005, 380, 257-259.	2.1	7
85	LRRK2 R1441G in Spanish patients with Parkinson's disease. Neuroscience Letters, 2005, 382, 309-311.	2.1	97
86	Clinical traits of LRRK2-associated Parkinson's disease in Ireland: A link between familial and idiopathic PD. Parkinsonism and Related Disorders, 2005, 11, 349-352.	2.2	38
87	Parkin genetics: one model for Parkinson's disease. Human Molecular Genetics, 2004, 13, 127R-133.	2.9	153
88	Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease. Neuroscience Letters, 2004, 370, 151-154.	2.1	65
89	Single-nucleotide polymorphisms in the promoter region of the PARKIN gene and Parkinson's disease. Neuroscience Letters, 2002, 329, 149-152.	2.1	23
90	Association between the TNFÎ±-308 A/G polymorphism and the onset-age of Alzheimer disease. American Journal of Medical Genetics Part A, 2002, 114, 574-577.	2.4	69